Neurosense Therapeutics Ltd (NRSN)

Mar 02, 2025

NeuroSense’s ALS drug PrimeC shows success in phase 2b, eyes final trial - The Jerusalem Post

Mar 02, 2025

Feb 27, 2025

The next rare disease roadblock: American innovation moving ex-U.S. - BioCentury

Feb 27, 2025

Feb 19, 2025

NeuroSense Therapeutics Reports Positive Phase 2b Study Results for ALS Treatment - TipRanks

Feb 19, 2025

Jan 14, 2025

NeuroSense Therapeutics Reports Key Progress and Financials - TipRanks

Jan 14, 2025

Jan 14, 2025

NeuroSense Therapeutics (NASDAQ:NRSN) Trading Down 0.4% – Here’s What Happened - Defense World

Jan 14, 2025

Jan 06, 2025

NeuroSense regains Nasdaq compliance with equity boost - Investing.com

Jan 06, 2025

Jan 06, 2025

NeuroSense regains Nasdaq compliance with equity boost By Investing.com - Investing.com Nigeria

Jan 06, 2025

Jan 06, 2025

NeuroSense Regains Nasdaq Compliance, Strengthens Position for ALS Treatment - TipRanks

Jan 06, 2025

Jan 06, 2025

NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement - StreetInsider.com

Jan 06, 2025

Jan 03, 2025

NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule - GuruFocus.com

Jan 03, 2025

Dec 31, 2024

NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development Summit - GuruFocus.com

Dec 31, 2024

Dec 28, 2024

NeuroSense's (NASDAQ:NRSN) ALS Drug Candidate Shows Promise In R - GuruFocus.com

Dec 28, 2024

Dec 25, 2024

Neurosense Therapeutics Ltd (NRSN-Q) QuotePress Release - The Globe and Mail

Dec 25, 2024

Dec 24, 2024

Analyzing NeuroSense Therapeutics (NASDAQ:NRSN) & Avidity Biosciences (NASDAQ:RNA) - Defense World

Dec 24, 2024

Dec 23, 2024

NeuroSense Partners with Pharma Giant to Propel ALS Drug PrimeC - TipRanks

Dec 23, 2024

Dec 23, 2024

NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS - Nasdaq

Dec 23, 2024

Dec 23, 2024

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Shares Bought by XTX Topco Ltd - Defense World

Dec 23, 2024

Dec 18, 2024

NeuroSense Advances ALS Treatment with PrimeC, Boosts Financial Position - TipRanks

Dec 18, 2024

Dec 18, 2024

NeuroSense Provides Business Update and Third Quarter 2024 Financial Results - citybiz

Dec 18, 2024

Dec 18, 2024

NeuroSense's ALS Drug Shows Breakthrough Results: 58% Better Survival Rate in Phase 2b Trial - StockTitan

Dec 18, 2024

Dec 18, 2024

NeuroSense Provides Business Update and Third Quarter 2024 Financial Results (PR Newswire) - Aktiellt

Dec 18, 2024

Dec 17, 2024

NeuroSense Therapeutics Regains Nasdaq Compliance - TipRanks

Dec 17, 2024

Dec 17, 2024

NeuroSense Therapeutics (NASDAQ:NRSN) Receives “Hold” Rating from Maxim Group - Defense World

Dec 17, 2024

Dec 16, 2024

Maxim cuts NeuroSense shares rating to hold on capital concerns By Investing.com - Investing.com South Africa

Dec 16, 2024

Dec 16, 2024

Maxim cuts NeuroSense shares rating to hold on capital concerns - Investing.com

Dec 16, 2024

Dec 15, 2024

Comparing Emmaus Life Sciences (OTCMKTS:EMMA) & NeuroSense Therapeutics (NASDAQ:NRSN) - Defense World

Dec 15, 2024

Dec 13, 2024

NeuroSense aligns with FDA on Phase 3 ALS drug study By Investing.com - Investing.com Australia

Dec 13, 2024

Dec 11, 2024

NeuroSense Receives FDA Approval for Phase 3 Study of ALS Treatment - TipRanks

Dec 11, 2024

Dec 11, 2024

NeuroSense Receives Positive FDA Feedback on Phase 3 Study Desig - GuruFocus.com

Dec 11, 2024

Dec 11, 2024

NeuroSense aligns with FDA on Phase 3 ALS drug study - Investing.com

Dec 11, 2024

Dec 11, 2024

NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC - Marketscreener.com

Dec 11, 2024

Dec 11, 2024

NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC (PR Newswire) - Aktiellt

Dec 11, 2024

Dec 06, 2024

Dewpoint Therapeutics and Mitsubishi Tanabe partner on ALS therapy - European Biotechnology News

Dec 06, 2024

Dec 04, 2024

NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS - The Malaysian Reserve

Dec 04, 2024

Dec 04, 2024

NeuroSense Announces Completion of PARADIGM Study Highlighting P - GuruFocus.com

Dec 04, 2024

Dec 04, 2024

NeuroSense Therapeutics Ltd. Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS - Marketscreener.com

Dec 04, 2024

Dec 04, 2024

NeuroSense’s PrimeC Shows Promise in ALS Treatment - TipRanks

Dec 04, 2024

Dec 03, 2024

NeuroSense Therapeutics Ltd. announced that it expects to receive $5 million in funding - Marketscreener.com

Dec 03, 2024

Dec 03, 2024

NeuroSense secures $5 million in private placement funds By Investing.com - Investing.com Nigeria

Dec 03, 2024

Dec 02, 2024

NeuroSense Therapeutics Announces Securities Purchase Agreement - TipRanks

Dec 02, 2024

Dec 02, 2024

NeuroSense Therapeutics Announces $5 Million Private Placement - citybiz

Dec 02, 2024

Dec 02, 2024

NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price - Lelezard

Dec 02, 2024

Dec 02, 2024

NeuroSense secures $5 million in private placement funds - Investing.com India

Dec 02, 2024

Nov 28, 2024

Exosome Diagnostics & Therapeutics Market Assessment 2025-2030 Featuring Strategic Profiles of the Industry's Leading and Emerging Players - GlobeNewswire

Nov 28, 2024

Nov 26, 2024

NeuroSense Therapeutics Plans to File for Early Commercializatio - GuruFocus.com

Nov 26, 2024

Nov 24, 2024

NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Tr - GuruFocus.com

Nov 24, 2024